Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
|Official Title:||Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics|
- Decreased cocaine-reinforced behavior [ Time Frame: Day 9 of treatment ]participants will make a series of choices between vouchers with an ascending monetary value and intravenous injections of cocaine
- Changes in cocaine pharmacokinetics [ Time Frame: Day 9 of treatment ]Plasma levels of cocaine and metabolites will be determined by liquid chromatography-tandem mass spectrometry
|Study Start Date:||October 2012|
|Estimated Study Completion Date:||November 2013|
|Estimated Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Placebo Comparator: Oral placebo
Drug: Oral placebo
Experimental: Oral tacrine
Drug: Oral tacrine
Tacrine, 160 mg per day, four times daily
Background Reinforcing effects of cocaine are believed to arise through release of dopamine (DA) at the nucleus accumbens by neurons in the ventral tegmental area. Activation of cholinergic receptors on the cell bodies of these neurons can enhance DA release. Elevated levels of acetylcholine (ACh) in the nucleus accumbens may also serve to inhibit appetitive behaviors. Cholinesterase inhibitors such as tacrine increase synaptic levels of ACh by preventing its inactivation by acetylcholinesterase (AChE) or butyrylcholinesterase (BuChE), and can improve learning and memory. In animals, cholinesterase inhibitors can attenuate cocaine self-administration and conditioned place preference. Tacrine is a centrally acting, reversible inhibitor of AChE and BuChE that is approved for treatment of Alzheimer's disease. In addition to its effects on the cholinergic system, tacrine can potentiate the actions of monoamines, including DA. Although use of tacrine has declined because of requirements for monitoring of potential liver toxicity and pharmacokinetics that necessitate multiple daily doses, it is more potent than other cholinesterase inhibitors in attenuating cocaine self-administration in animals. Pretreatment with tacrine can produce long-lasting reductions in cocaine-reinforced behavior in rats, described as persistent attenuation (cocaine self-administration is decreased by more than 80% over a period of three days during which no additional cholinesterase inhibitor is administered, see Figure 1). No previous studies have evaluated whether tacrine can modify the effects of cocaine in humans.
Rationale To our knowledge, tacrine is the only compound that can produce persistent attenuation in rats treated with clinically relevant doses. If similar effects were observed in humans, this would lead to an important paradigm shift for substance abuse treatment, in that large reductions in cocaine-reinforced behavior could be produced without the need for continuous dosing with a medication. This scenario could remove the requirement for continued compliance with oral dosing in some patients with its associated potential for toxicity.
- Evaluate whether tacrine treatment causes persistent attenuation of cocaine-reinforced behavior in humans.
- Determine the effectiveness of pretreatment with tacrine in attenuating cocaine-induced craving.
- Evaluate plasma levels of cocaine and characterize the bioavailability of tacrine in individual patients.
Methods This is a randomized, double-blind, double-dummy, placebo-controlled, inpatient, single-center, parallel-group evaluation of the potential for oral tacrine to modify cocaine self-administration, cocaine-induced craving, and the pharmacokinetics of cocaine and tacrine. To evaluate the occurrence of persistent attenuation, the subjective and reinforcing effects of intravenous cocaine will be determined during oral treatment and three days following its discontinuation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01406522
|United States, Missouri|
|Kansas City VA Medical Center|
|Kansas City, Missouri, United States, 64128|
|Principal Investigator:||Kenneth W Grasing, M.D.||Kansas City VA Medical Center|